by
Lisa Chamoff, Contributing Reporter | July 19, 2021
From the July 2021 issue of HealthCare Business News magazine
“What a tool like this represents is the potential to screen 40 million women a year for heart disease in the U.S. alone,” said Kevin Harris, the president of CureMetrix, who estimates a $30 billion healthcare economic impact over five years.
The company is signing research agreements with institutions across the country and is aiming to have the product FDA-cleared by the end of the year.
Densitas
This year, Densitas updated its densitas intelliMammo A.I. Platform. The product brings together the company’s qualityAI, densityAI and riskAI solutions, and was expanded with a novel solution to simplify compliance with MQSA EQUIP criteria. It shows image quality metrics by technologist, and by machine and site, many different factors, providing reports and corrective action documentation. The image quality metrics also enable mammography educators to develop customized evidence-based training curriculums.
“We have worked with mammography educators to provide image quality metrics and positioning tips at the technologist’s fingertips,” said Mo Abdolell, chief executive officer of Densitas.
Fujifilm Tomo Spot Paddle
FUJIFILM Medical Systems U.S.A., Inc.
This past year, Fujifilm introduced a new 18-centimeter-by-24-centimeter tomo spot paddle with 10-centimeter round compression for the ASPIRE Cristalle digital mammography system. This paddle targets a suspicious area for compression and allows for tissue visualization outside of the round spot area, keeping the metal frame completely outside of the image.
The panel was developed based on customer feedback, said Christine Murray, women’s health project manager for FUJIFILM Medical Systems U.S.A., Inc.
“With other paddles, the spot is the only thing you’re going to be imaging,” Murray said. “Our new paddle allows some additional compression outside the area of focus.”
The company also expanded its partnership with Volpara Health and is using its VolparaLive! and Volpara Enterprise.
GE Healthcare
Last year, GE Healthcare introduced Serena Bright, the industry’s first contrast-enhanced guided biopsy solution. The technology allows clinicians to conduct breast biopsy exams with contrast guidance using the same mammography equipment, in the same room and with the same staff as the screening or diagnostic mammogram, which can be done faster and at a lower cost than an MR-guided biopsy.
